Librarian Bot: Add base_model information to model

This pull request aims to enrich the metadata of your model by adding [`t5-small`](https://huggingface.co./t5-small) as a `base_model` field, situated in the `YAML` block of your model's `README.md`.

How did we find this information? We performed a regular expression match on your `README.md` file to determine the connection.

**Why add this?** Enhancing your model's metadata in this way:
- **Boosts Discoverability** - It becomes straightforward to trace the relationships between various models on the Hugging Face Hub.
- **Highlights Impact** - It showcases the contributions and influences different models have within the community.

For a hands-on example of how such metadata can play a pivotal role in mapping model connections, take a look at [librarian-bots/base_model_explorer](https://huggingface.co./spaces/librarian-bots/base_model_explorer).

This PR comes courtesy of [Librarian Bot](https://huggingface.co./librarian-bot). If you have any feedback, queries, or need assistance, please don't hesitate to reach out to [@davanstrien](https://huggingface.co./davanstrien). Your input is invaluable to us!

README.md

@@ -1,4 +1,6 @@
 ---
+language:
+- en
 license: apache-2.0
 tags:
 - generated_from_trainer
@@ -11,15 +13,33 @@ tags:
 - tagging
 metrics:
 - rouge
-model-index:
-- name: t5-small-machine-articles-tag-generation
-  results: []
 widget:
-- text: "Paige, AI in pathology and genomics\n\nFundamentally transforming the diagnosis and treatment of cancer\nPaige has raised $25M in total. We talked with Leo Grady, its CEO.\nHow would you describe Paige in a single tweet?\nAI in pathology and genomics will fundamentally transform the diagnosis and treatment of cancer.\nHow did it all start and why? \nPaige was founded out of Memorial Sloan Kettering to bring technology that was developed there to doctors and patients worldwide. For over a decade, Thomas Fuchs and his colleagues have developed a new, powerful technology for pathology. This technology can improve cancer diagnostics, driving better patient care at lower cost. Paige is building clinical products from this technology and extending the technology to the development of new biomarkers for the biopharma industry.\nWhat have you achieved so far?\nTEAM: In the past year and a half, Paige has built a team with members experienced in AI, entrepreneurship, design and commercialization of clinical software.\nPRODUCT: We have achieved FDA breakthrough designation for the first product we plan to launch, a testament to the impact our technology will have in this market.\nCUSTOMERS: None yet, as we are working on CE and FDA regulatory clearances. We are working with several biopharma companies.\nWhat do you plan to achieve in the next 2 or 3 years?\nCommercialization of multiple clinical products for pathologists, as well as the development of novel biomarkers that can help speed up and better inform the diagnosis and treatment selection for patients with cancer."
+- text: "Paige, AI in pathology and genomics\n\nFundamentally transforming the diagnosis\
+    \ and treatment of cancer\nPaige has raised $25M in total. We talked with Leo\
+    \ Grady, its CEO.\nHow would you describe Paige in a single tweet?\nAI in pathology\
+    \ and genomics will fundamentally transform the diagnosis and treatment of cancer.\n\
+    How did it all start and why? \nPaige was founded out of Memorial Sloan Kettering\
+    \ to bring technology that was developed there to doctors and patients worldwide.\
+    \ For over a decade, Thomas Fuchs and his colleagues have developed a new, powerful\
+    \ technology for pathology. This technology can improve cancer diagnostics, driving\
+    \ better patient care at lower cost. Paige is building clinical products from\
+    \ this technology and extending the technology to the development of new biomarkers\
+    \ for the biopharma industry.\nWhat have you achieved so far?\nTEAM: In the past\
+    \ year and a half, Paige has built a team with members experienced in AI, entrepreneurship,\
+    \ design and commercialization of clinical software.\nPRODUCT: We have achieved\
+    \ FDA breakthrough designation for the first product we plan to launch, a testament\
+    \ to the impact our technology will have in this market.\nCUSTOMERS: None yet,\
+    \ as we are working on CE and FDA regulatory clearances. We are working with several\
+    \ biopharma companies.\nWhat do you plan to achieve in the next 2 or 3 years?\n\
+    Commercialization of multiple clinical products for pathologists, as well as the\
+    \ development of novel biomarkers that can help speed up and better inform the\
+    \ diagnosis and treatment selection for patients with cancer."
   example_title: 'ML Article Example #1'
-language:
-- en
 pipeline_tag: summarization
+base_model: t5-small
+model-index:
+- name: t5-small-machine-articles-tag-generation
+  results: []
 ---
 
 <!-- This model card has been generated automatically according to the information the Trainer had access to. You